Zahra Tavassoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zahra Tavassoli has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Maleki Ahmadabadi
Department of Pharmacy Medicine, School of Pharmacy, Baku University of Medical, Baku, Azerbaijan
1 shared publication - Alireza Habibzadeh
Department of Pharmacy Medicine, School of Pharmacy, Baku University of Medical, Baku, Azerbaijan
1 shared publication - Anahita Kalirad
Department of Radiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Aref Zarei
Department of Nursing, School of Nursing and Midwifery, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication - Babak Gholamine
Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Elahe Zaremoghadam
Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication
Latest Publications
- Open Access
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Investigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites
- 29 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 13 (1)
Open AccessInvestigating the association between the administration of SGLT-2 inhibitors and the risk of urinary tract infection; a systematic review and meta-analysis
Introduction: Sodium-glucose transporter 2 (SGLT-2) inhibitors induce glycosuria. Therefore, using a meta-analysis study, this study aimed to evaluate the correlation between SGLT2 inhibitor administration and urinary tract infection (UTI) risk. Materials and Methods: In this systematic review and meta-analysis, we conducted searches on Scopus, PubMed, Web of Science, Cochrane, and Google Scholar without time limitations up to October 16, 2023. Data were analyzed using STATA 14 software, and a significance level of P < 0.05 was considered. Results: The combination of 11 studies revealed that the use of SGLT2 inhibitors, when compared to glucagon-like peptide-1 (GLP-1) receptor agonists, reduced the risk of UTI (OR = 0.77; 95% CI: 0.62, 0.95) and when compared to insulin (OR = 0.74; 95% CI: 0.63, 0.87). However, the administration of SGLT2 inhibitors, when compared to dipeptidyl peptidase‐4 (DPP‐4) inhibitors (OR = 1.09; 95% CI: 0.90, 1.32), sulfonylureas (OR = 1.35; 95% CI: 0.88, 2.05), biguanide initiators (OR = 1.14; 95% CI: 1.05, 1.24), thiazolidinediones (OR = 1.19; 95% CI: 0.58, 2.44), and other antidiabetic drugs (OR = 1.20; 95% CI: 0.92, 1.57), did not increase the risk of UTI. The administration of dapagliflozin (OR = 1.51; 95% CI: 0.60, 3.81), canagliflozin (OR = 1.22; 95% CI: 0.47, 3.15), and empagliflozin (OR = 3.22; 95% CI: 2.97, 3.48) showed associations with UTI risk. Furthermore, the correlation between SGLT2 inhibitors use and UTI risk was observed in cohort studies (OR = 1.14; 95% CI: 0.98, 1.32), cross-sectional studies (OR = 0.86; 95% CI: 0.64, 1.14), in males (OR = 1; 95% CI: 0.72, 1.40), and females (OR = 1.17; 95% CI: 0.91, 1.52). Conclusion: Empagliflozin, in contrast to dapagliflozin and canagliflozin, increases the risk of UTI. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (CRD42023479548) and Research Registry (UIN: reviewregistry1742) Websites
- Open Access
- 27 January 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Pulmonary radiologic findings based on Warrick score as a predictor of COVID-19 patients’ outcomes
Introduction: Predicting factors related to the severity and mortality of coronavirus disease 2019 (COVID-19) patients can significantly help in better management of their treatment. Objectives: This study aimed to investigate the correlation between pulmonary radiologic findings based on the Warrick score and COVID-19 patients’ outcomes. Patients and Methods: This descriptive-analytical study was conducted on 436 COVID-19 patients hospitalized at Shahid Mohammadi hospital in Bandar Abbas. Pulmonary radiologic findings were scored based on the Warrick score. Outcomes of COVID-19 patients, including disease severity and mortality, were followed. Independent T-test and binary logistic regression were conducted to explore the correlation between the pulmonary radiologic findings and patients’ outcomes. Results: Results showed that the correlation between pulmonary radiologic findings with both disease severity and mortality was significant, since higher pulmonary involvement caused greater severity and mortality. The Warrick score difference between dead and recovered patients and low and high disease severity were significant, therefore greater Warrick score caused more disease severity and mortality. Conclusion: Pulmonary radiologic findings based on the Warrick score can use as a predictor of COVID-19 patients’ outcomes.
- 27 January 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Open AccessPulmonary radiologic findings based on Warrick score as a predictor of COVID-19 patients’ outcomes
Introduction: Predicting factors related to the severity and mortality of coronavirus disease 2019 (COVID-19) patients can significantly help in better management of their treatment. Objectives: This study aimed to investigate the correlation between pulmonary radiologic findings based on the Warrick score and COVID-19 patients’ outcomes. Patients and Methods: This descriptive-analytical study was conducted on 436 COVID-19 patients hospitalized at Shahid Mohammadi hospital in Bandar Abbas. Pulmonary radiologic findings were scored based on the Warrick score. Outcomes of COVID-19 patients, including disease severity and mortality, were followed. Independent T-test and binary logistic regression were conducted to explore the correlation between the pulmonary radiologic findings and patients’ outcomes. Results: Results showed that the correlation between pulmonary radiologic findings with both disease severity and mortality was significant, since higher pulmonary involvement caused greater severity and mortality. The Warrick score difference between dead and recovered patients and low and high disease severity were significant, therefore greater Warrick score caused more disease severity and mortality. Conclusion: Pulmonary radiologic findings based on the Warrick score can use as a predictor of COVID-19 patients’ outcomes.